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ORIGINAL RESEARCH
Background: Drug-related problems (DRPs) have been shown to prevail in hospitalized
patients, and polypharmacy and increasing age have been identified as two important risk
factors.
Objective: We investigated the occurrence of DRPs and adverse drug reactions (ADRs)
amongst hospitalized patients prescribed polypharmacy, and the association of advanced age
and female gender.
Method: A retrospective cross-sectional study was performed in an acute-care hospital in
Singapore. Only patients prescribed polypharmacy were included. Mann-Whitney test was
used to test for significant difference between the age and gender of patients and their risk of
acquiring DRPs. The relative risks of developing DRP and ADR for geriatric patients and
female patients were estimated.
Results: Of 347 patients prescribed polypharmacy (43% female and 58.2% geriatrics), no
statistical correlations were observed between age and gender with developing DRPs. An
increased number of medications was associated with higher risk for patients with DRPs on
admission (p = 0.001), but not for inpatients with DRPs (p = 0.119). Results from patients
with ADRs showed that the relative risk (RR) of geriatrics prescribed polypharmacy and major
polypharmacy (10 and more drugs) were 1.01 and 1.23, respectively. Female patients had a
RR of 0.79 compared with male patients in developing ADRs.
Conclusion: Results showed that among patients with polypharmacy, age and gender may
not be as important as number of drugs prescribed as predictors of experiencing a DRP. A
similar trend was observed in the development of ADRs.
Keywords: polypharmacy, drug-related problems, adverse drug reactions, geriatrics
Introduction
Drug-related problems (DRPs), which include adverse drug reactions (ADRs),
unnecessary drug therapy, inappropriate choice of drugs, and untreated conditions,
have been shown to prevail in hospitalized patients, with a reported incidence rate as
high as 25% (Steel et al 1981; Stewart and Cooper 1994). Undeniably, many factors
can contribute to the high prevalence rate, but polypharmacy and older age have
often been identified as important risk factors (Nolan and O’Malley 1988; Montamat
and Cusack 1992; Stewart and Cooper 1994).
Polypharmacy is defined as the use of multiple medications by a single patient
and is commonly observed among geriatric patients (Stewart and Cooper 1994). The
use of multiple medications has been shown to predispose patients to ADRs
(Williamson and Chopin 1980; Inman 1985; Nolan and O’Malley 1988; Hoigné et al
1990; Chrischilles et al 1992), drug–drug interactions (McInnes and Brodie 1988;
Beers and Ouslander 1989; Stewart and Cooper 1994), and medication noncompliance
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(Bergman and Wiholm 1981a; Ramsay and Tucker 1981;
Gillum and Barsky 1984), particularly in the geriatric
population.
Among the potential contributing factors of DRPs, the
association between polypharmacy and the incidence of
ADRs has been most widely studied and documented.
Incidences of ADR have been consistently shown to increase
in an exponential rather than a linear manner with the
number of drugs taken (Hurwitz and Wade 1969; Morgan
et al 1988; Nolan and O’Malley 1988; Cadieux 1989). For
example, significantly more ADR-associated hospital
admissions have been observed among patients prescribed
four or more drugs than those receiving up to three drugs
(11.1% vs 3.6%) (Bergman and Wiholm 1981b). In another
study, it was reported that hospitalized patients who
experienced an adverse reaction took twice as many drugs
(12.5 vs 6.3 drugs) as patients without ADRs (Hurwitz and
Wade 1969). Besides the undesirable clinical consequences
for the patients, ADRs also pose a significant financial
burden to the healthcare system (Beers et al 1992). In a US
study performed in 1992–1994, the estimated cost of treating
reported adverse drug events among inpatients was US$1.5
million per year at a university-affiliated hospital (Schneider
et al 1995). Another more recent French study conducted in
1996–1997 showed the annual cost of drug-related hospital
admission to a university hospital as €3.85 million per year
(Lagnaoui et al 2000). Thus, reducing the use of unnecessary
medicines and avoiding polypharmacy would be beneficial
in aiding the reduction of healthcare cost beyond the confines
of reduction in drug costs alone.
Of the risk factors, advanced age has been associated
with substantial increased risk of acquiring ADR (Gurwitz
et al 1990). A sevenfold increase in occurrence of ADRs
from 3% to 21% has been shown to occur between patients
aged 20–30 years and 60–70 years (Hurwitz 1969). In
addition, many studies have shown that a large number of
emergency room visits and hospital admissions amongst
older people could be attributed to iatrogenic syndromes
associated with polypharmacy (Grymonpre et al 1988; Colt
and Shapiro 1989; Scheneider et al 1992; Stuck et al 1994;
Hanlon et al 1997). Hence, polypharmacy plus old age could
be considered a potent combination for ADRs to take place.
The high risk of developing ADRs in patients with both
risk factors was demonstrated when 35% of a study
population of 167 older patients prescribed polypharmacy
(taking 5 or more drugs) experienced a confirmed adverse
drug event over a one-year period (Hanlon et al 1997).
However, other researchers had argued that this
propensity of older patients experiencing ADRs was not
being well substantiated by epidemiological data (Hoigné
et al 1990). Furthermore, the failure to control for important
age-related covariates (eg, clinical status of the patient) had
also been cited as a limitation to the interpretation of many
study results (Gurwitz and Avorn 1991). Some researchers
proposed that inappropriate medication in the elderly might
pose a higher risk for acquiring ADR than advanced age as
a sole risk factor (Lindley et al 1992). Up to now, the issue
of whether inappropriate drug use or advanced age should
be considered the more important risk factor for developing
DRPs remains unresolved. The resolution of this issue is of
great relevance to the practice of clinical medicine, as it
would allow physicians and pharmacists to focus more
attention on patients with the “true” risk factors.
Another interesting observation about the studies relating
to DRPs is that there exists little data on comprehensive
DRPs among hospitalized patients. So far, most studies
published had addressed either the problem of drug-related
admissions to hospitals (Bergman and Wiholm 1981a; Bero
et al 1991; Hallas et al 1992; Prince et al 1992; Courtman
and Stallings 1995; Fattinger et al 2000), or focused only
on ADRs among hospitalized patients (Hurwitz and Wade
1969; Brennan et al 1991; Classen et al 1997). A more
comprehensive study of DRPs in hospitalized patients would
provide valuable insights for the healthcare professionals
trying to reduce the incidence of DRPs.
Finally, another issue that is pertinent to healthcare
delivery and risk management is the impact of the numerous
studies of DRPs on clinical practice. As most of the studies
were performed between 10 and 20 years ago, it is unclear
whether the results and lessons learnt from these studies
have any influence on changing clinical practices. An
assessment of the current situation would assist the
healthcare providers in optimising intervention strategies
according to needs and available resources.
In the current study, we attempted to evaluate some of
the aforementioned issues. As polypharmacy is associated
with the increased occurrence of DRPs (Bergman and
Wiholm 1981b; Nolan and O’Malley 1988; Hallas et al 1992;
Lindley et al 1992; Green et al 2000), our main objectives
were to investigate the occurrence of all DRPs (at admissions
and while hospitalized) among hospitalized patients
prescribed polypharmacy, and to evaluate the association
of two risk factors, namely advanced age and female gender,
with DRPs and ADRs in particular.Therapeutics and Clinical Risk Management 2005:1(1) 41
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Since advanced age has always been associated with
higher incidence of DRPs (Hurwitz and Wade 1969;
Williamson and Chopin 1980; McMillan et al 1986; Beijer
and De Blaey 2002), we wanted to see if this trend could be
confirmed or supported by our local data. Also, female
patients, being generally lighter in weight and smaller in
build than their male counterparts but usually receiving the
same drug doses, had been demonstrated to be more prone
to ADRs in some studies (Bergman and Wiholm 1981b;
Veehof et al 1999; Fattinger et al 2000). This is most
probably attributable to the exposure to higher dose per body
weight for the females. We postulated that this trend would
be more pronounced in our predominantly Asian female
patients (who are generally even lighter in weight than
Caucasian counterparts).
In addition to helping to resolve the abovementioned
issues, the results from this study could provide baseline
information quantifying the problem of DRPs among
hospitalized patients receiving polypharmacy in Singapore,
and contribute to the formulation and implementation of
risk management strategies.
Methods
Study population
We conducted a retrospective, cross-sectional study in a 404-
bed acute-care hospital in Singapore. Inpatient case notes
and medication records were used in our data collection.
Subjects were included in the study if they were inpatients
on the last two Thursdays of November and December 2000,
and who satisfied the criteria of being prescribed
polypharmacy (see definition below). Thursday was chosen
to ensure that the patients admitted over the weekend would
have had their admitting medications checked or altered by
the attending physicians. This would capture most DRPs
(both causing admissions and those occurring during
hospitalization) among these patients.
Definitions
DRP was defined as an event or circumstance that involves
a patient’s drug treatment that actually, or potentially,
interferes with the achievement of an optimal outcome
(Hepler and Strand 1990).
For ADRs, we used the World Health Organization
definition which specifies an adverse reaction as a reaction
which is noxious and unintended, and which occurs at
dosages normally used for prophylaxis, diagnosis, therapy
of disease, or for the modification of physiological function
(WHO 1972).
Polypharmacy was defined as the daily consumption of
5 or more medications. Different strengths of the same drug
were counted as one item. However, formulations of the
one drug requiring different routes of administration were
regarded as separate items. Combination drug, that is a drug
with more than one active ingredient in it, was regarded as
a single item.
Data collection
Patient’s age, gender, principal diagnosis, concomitant
disease states, medical history, concurrent medications and
dosage, and medications taken prior to admission were
recorded. Other data collected included biochemistry and
hematology results, microbiological culture and sensitivity
tests, and plasma drug concentrations when these were
available. Normal laboratory values for the hospital were
used to determine the presence of abnormalities. Renal
function was estimated from creatinine clearance (Cockcroft
and Gault 1976). DRPs experienced by the patients on
admission and during their inpatient stay, together with the
suspected drugs were extracted from their medical records.
To avoid inter-rater variation, the case notes and medication
records of the patients were reviewed by one of the
investigators (YK), and any need for confirmation of the
decision was resolved with the other investigators.
Classification of DRPs
DRPs were defined as inappropriate treatments, potential
drug interactions, inappropriate dosages, unsafe drugs for
patients, and ADRs experienced by patients on admission
and during their inpatient stay. ADRs that occurred during
the same period were characterized based on the drugs and
drug class involved, the manifestations of these ADRs, and
the frequency of occurrence. Due to the retrospective nature
of the study, ADRs and their potential causality drugs were
extracted from patients’ medical case notes with no further
evaluation and determination into the ADR causality.
Based on the case notes, the patients’ existing conditions
were matched with their drug therapy. Appropriate doses of
drugs, appropriate drug indications, possible drug
interactions, and ADRs were based on drug monographs in
the 42nd edition of the British National Formulary (BNF
Joint Formulary Committee 2002).
The appropriateness of control was based on the
physician’s documentation of the patient’s condition in theTherapeutics and Clinical Risk Management 2005:1(1) 42
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medical case notes, together with any available laboratory
results. For any documentation of a poorly controlled
medical condition, the medication records were reviewed
thoroughly to determine if the poor control was drug related
(ie, if the patient was receiving adequate and/or appropriate
medication at that time). Inappropriately controlled
conditions due to lack of medications, or lack of synergistic
medications, would be classified as “additional therapy
required”, while a drug was prescribed for no obvious
indication would be classified as “unnecessary drug
therapy”.
In assessing the appropriateness in the choice of drugs,
Beer’s explicit criteria (Beers 1997) were used to identify
medications that were deemed unsuitable for use in elderly
patients more than 65 years old.
Statistical analysis
Chi-square test was employed to test for significant
difference between the age of patients, as well as the gender
of patients and their risk of getting DRPs. Mann-Whitney
test was used to test for significant difference between the
number of medications taken and the risk of DRPs. In all
comparisons, the level of significance was adopted as 0.05.
The relative risks of developing ADR and DRP for
geriatric patients and female patients were estimated from
the prevalence of these events compared with non-geriatrics
and male patients, respectively.
Results
Characteristics of study population
There were 640 inpatients during the study period. Data
were collected for 347 patients (54.2%) prescribed
polypharmacy. Their age ranged from 16 to 97 years (mean
65.9 ± 17.7 years). Of the subjects recruited, 43% were
female. Geriatric patients (patients more than 65 years old)
made up 58.2% of our study population.
Medication profile
The number of medications per patient ranged from 5 to 14
(mean 7.4 ± 2.1). Paracetamol was the most commonly used
drug (33.4%) followed by two laxatives, senna and lactulose
(prescribed in 30.3% and 29.7%, respectively). A total of
181 patients (52.2% of our study population) were taking
laxatives; of which, 13 patients (3.7%) were on 3 laxatives
and 80 patients (23.1%) were on 2 laxatives simultaneously.
The ten most commonly prescribed medicines are shown in
Table 1.
DRPs on admission
There were 32 cases of DRPs which resulted in, or were
coincidental with admission. They could be classified into
4 broad categories: requiring additional therapy (31.3%),
non-compliance (28.1%), adverse drug reactions (25%), and
inappropriate dosing (dose too low 12.5%, dose too high
3.1%).
For the 10 patients who required additional therapy, the
existing medical conditions of nine may have been better
controlled if synergistic drugs were added onto their current
medication. The tenth patient was admitted as a result of
syncope secondary to chronic anemia which was not treated
with medication.
Of the noncompliant patients, one of them had poor
inhaler technique resulting in the exacerbation of his asthma
problem. The remaining 8 patients were not compliant with
their medication regime. Details of the DRPs during
admission are published elsewhere (see Koh et al 2003).
Table 1 Ten most commonly prescribed drugs
Number of
Drug  patients
a (%)
b
Paracetamol 116 33.4
Senna 105 30.3
Lactulose 103 29.7
Sangobion 70 20.2
Aspirin 67 19.3
Isosorbide dinitrate 55 15.9
Potassium chloride 51 14.7
Amlodipine 50 14.4
Famotidine 50 14.4
Enalapril 42 12.1
a Those who are receiving the drug.
b The percentage of study population receiving the drug.
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Figure 1 Drug-related problems and their number of incidences identified in
patients during hospital stay. Abbreviation: ADRs, adverse drug reactions.Therapeutics and Clinical Risk Management 2005:1(1) 43
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DRPs during hospital stay
The types of DRPs identified during the study period
included: (1) inappropriate treatment (comprises additional
therapy, unnecessary drug therapy, and use of inappropriate
drug); (2) potential drug interactions; (3) inappropriate
dosages – dose too high or dose too low; (4) unsafe drug
for patients; and (5) ADRs (Figure 1).
Of the 149 incidences of inappropriate treatment, 118
had an untreated condition that required additional therapy,
with anemic patients (identified by their biochemistry
results) making up 64.4% of this group. Another 9 patients
would require additional drugs to improve the management
of their existing medical conditions. For patients receiving
unnecessary drug therapies, 5 had no recorded medical
indication for their prescribed medications and the remaining
patients were prescribed duplicate therapies (Figure 2).
Patients taking drugs not recommended for their conditions
made up the remaining 17 cases of inappropriate treatment.
Of these, 82.4% was due to usage of a particular drug when
contraindicated (eg, the use of propranolol in an asthmatic),
and the rest was due to using a drug when the condition was
already refractory to it (eg, using ciprofloxacin when culture
and sensitivity results showed bacterial resistance) or when
a particular drug was not even indicated for the condition
(eg, prescribing paracetamol for giddiness).
For inappropriate dosages, the cases encountered were
wrongly prescribed dosages, inappropriate administration
frequencies, or the serum drug concentrations were higher
or lower than recommended ranges during therapeutic drug
monitoring. For some patients, the dosages of their
medications were deemed as too high when we took into
account their abnormal hepatic or renal function (Table 2).
Each combination of the drugs prescribed for the patients
during their hospitalization were checked for potential
interaction, and the top ten drugs/drug classes that were most
likely to be involved in causing drug–drug interactions are
listed in Figure 3. We only managed to identify cases of
potential drug interactions during hospital stay as the
documentation of drugs which the patients were on prior to
admission was not comprehensive for all the patients.
The 47 cases of unsafe drug regimes during
hospitalization were based on Beer’s criteria, which
identifies drugs unsuitable for use in patients more than 65
years old. Again, we could not identify unsafe drug usage
for patients on admission due to limited documentation.
Drug-pairs identified in our study that could give rise to
potential severe interaction are shown in Table 3.
With regards to the analysis of risk factors, there were
no statistical correlations when age and gender were
compared between patients with and without DRPs, both
on admission and during hospital stay. However, based on
Mann-Whitney test, the number of medications prescribed
for patients was not a risk factor for the presence of DRPs
Table 2 Dose of medication too high for existing renal or
hepatic function
Impaired Number
Drug  function  of patients
Enalapril Renal 4
Metronidazole Hepatic 2
Allopurinol Renal 1
Cefuroxime Renal 1
Fluoxetine Renal 1
Tolbutamide Renal 1
Tramadol Renal 1
Table 3 Significant potential drug interactions
Drug pair Possible effects
Atenolol + nifedipine Severe hypotension and heart failure
occasionally
Phenytoin + folic acid Decrease plasma level of phenytoin
Simvastatin + erythromycin Increase risk of myopathy
Simvastatin + warfarin Enhanced anticoagulant effect
SSRI + valproate Convulsion threshold lowered
Theophylline + calcium
channel blocker Possibly enhanced theophylline effect
Abbreviation: SSRI, selective serotonin reuptake inhibitor.
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drug–drug interactions.
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(p = 0.119) during hospital stay, but it was a risk factor for
patients with DRPs on admission (p = 0.001).
ADR analysis
There were 8 cases of identified ADRs on admission and
26 cases that occurred in 33 patients during hospital stay
(one patient experienced two ADRs during the study period).
Due to their small number of occurrence, we did an
aggregated analysis of all the ADR cases (Table 4). Patients
suspected of experiencing an ADR were taking a mean of
8.2 (± 2.6) different medicines compared with those not
having an ADR with a mean of 7.3 (± 2.1) medicines
(p = 0.015). Of those who experienced ADRs, 60.6% were
geriatrics. This formed about 10% of the geriatric patients
in our study, and 36.4% of these geriatric patients were
female.
Based on the results, the relative risk for geriatrics above
65 years in our study to develop ADRs was 1.01 (95%
confidence interval (CI): 0.52, 1.85), and the relative
risk for female patients in developing ADRs was 0.79
(95% CI: 0.40, 1.55). However, when we did the same
analysis for patients on major polypharmacy (10 or more
drugs) the relative risks for geriatrics and female patients
developing ADRs were 1.23 (95% CI: 0.36, 4.25) and 0.66
(95% CI: 0.21, 2.02), respectively.
The prevalence rates of developing DRPs and ADRs for
the various patient subgroups during the study period are
summarized in Table 5.
Discussion
Polypharmacy is a ubiquitous problem plaguing nearly all
healthcare systems. Here, we investigated the occurrence
of not only ADRs, but all DRPs on admission and during
hospitalization among patients receiving polypharmacy. An
evaluation of the status and possibly the risk factors involved
in DRPs would give us some basic information for working
towards improving the current situation.
From our results, nearly 10% of our study population
had at least one DRP at admission. However, this might be
an underestimate due to the lack of comprehensive
Table 4 Identified cases of adverse drug reactions
Drug class Drugs Manifestations of ADRs Number of patients
NSAIDs Aspirin Coffee ground vomitus 4
Bleeding GIT 2
Epigastric pain with vomiting 1
Gastric ulcer 1
ACE inhibitor Enalapril Declining renal function 1
Chronic cough with wheezing 1
Postural hypotension 1
Antiepileptics Carbamazepine Hyponatremia 1
Thrombocytopenia 1
Phenytoin Giddiness 1
Valproate Tremors 1
SSRIs Fluvoxamine Hyponatremia 1
Increased INR 1
Increased liver function tests 1
Fluoxetine Hyponatremia 1
Loop diuretic Frusemide Dehydration 2
Increased liver function tests 1
Calcium channel blocker Amlodipine Postural hypotension 2
Antiplatelet Ticlopidine Generalized rash 1
Decreased hemoglobin 1
Analgesic/antipyretic Paracetamol Itch 1
Antiarrythmic Procainamide Antiphopholipid syndrome 1
Antibiotic Ethambutol Generalized rash 1
Antipsychotic Sulpiride Extrapyramidal side effects 1
Beta-blocker Propranolol Asthma exacerbation 1
Fibrinolytic Streptokinase Rigors and facial flushing 1
Statins Simvastatin Increased liver function tests 1
Sulfonylurea Glipizide Increased liver function tests 1
Abbreviations: ADRs, adverse drug reactions; NSAIDs, nonsteroidal antiinflammatory drugs; ACE, angiotensin converting enzyme; SSRIs, selective serotonin reuptake
inhibitors; GIT, gastrointestinal tract; INR, international normalized ratio.Therapeutics and Clinical Risk Management 2005:1(1) 45
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documentation at the point of admission. Comparatively,
63.4% of our study population (ie, approximately 3 out of 5
patients) had at least one DRP, albeit theoretical or actual,
during their hospitalization. However, there was no
equivalent comparison found in the published literature since
we recruited only patients who were prescribed
polypharmacy. Nevertheless, the high percentage of patients
developing DRP here does highlight the need for more
attention to the group of patients prescribed polypharmacy.
Although we separated those DRPs present on admission
and those discovered while hospitalized, they will be
discussed as a whole with emphasis on potential drug–drug
interaction, appropriate dosages, and ADRs, as these DRPs
might have been preventable if proper checks were carried
out by physicians and pharmacists.
Our analysis on DRPs showed that potential drug–drug
interactions accounted for a substantial amount of potential
drug toxicity (34.8%). Numerous drug combinations that
resulted in modification of pharmacological action or in drug
toxicity have been documented (D’Arcy and Griffen 1986).
In the present study, 59% of possible drug–drug interaction
occurred in geriatric patients. The drugs most implicated
were β-blockers (namely, atenolol and propranolol),
nonsteroidal antiinflammatory agents (NSAIDs) (including
aspirin, ketoprofen, diclofenac, and mefenamic acid), and
angiotensin converting enzyme (ACE) inhibitors. This is
consistent with published data citing that the average number
of drug–drug interactions involving anticoagulants and
antihypertensives were significantly higher than other drug
groups (May et al 1977).
In addition, we also identified drug-pairs in our study
that could give rise to potential severe interaction (Table 3).
We acknowledge that the judgment here is based on
theoretical consideration. In clinical practice, some of these
combinations may still be used, but the patient will need to
be closely monitored for manifestations such as lack of
therapeutic efficacy or toxicity, especially for drugs whose
therapeutic effects may be diminished or augmented when
used in those combinations. As drug interactions can affect
patient’s clinical outcome, quality of life, as well as
contribute to unnecessary healthcare cost, the high
prevalence rate (~30%) in this study would make this an
important area requiring further investigation. As the study
was carried out prior to the introduction of clinical pharmacy
services at the study hospital, future pharmacists should
focus on reviewing patients’ medication charts and checking
for potential drug interactions.
Another common aspect of DRPs is inappropriate
dosages of medicines. Medication dosages were not adjusted
for 11 patients with either renal or hepatic impairment. This
made up 15.3% of all the patients receiving inappropriate
drug dosages, and 2.4% of the entire DRPs in this study.
Again, this might be an underestimate as the documentation
in the patient’s case notes was not very comprehensive and
Table 5 Prevalence rates of developing DRPs and ADRs for the various patient subgroups
Prevalence rate
Minor Major
Polypharmacy  polypharmacy  polypharmacy
Patients % (n/N)
a % (n/N)
a % (n/N)
a
DRP
All study patients 72.0 250/347 70.2 203/289 81.0 47/58
Less than 65 years old with DRP 72.9 102/140 74.2 89/120 65.0 13/20
65–74 years old with DRP  71.6 53/74 67.3 37/55 84.2 16/19
7–84 years old with DRP 69.0 58/84 64.3 45/70 92.9 13/14
85 years old and above with DRP 75.5 37/49 72.7 32/44 100 5/5
Female patients with DRP 41.2 103/250 37.4 76/203 57.4 27/47
Male patients with DRP 58.8 147/250 62.6 127/203 42.6 20/47
ADR
All study patients 9.5 33/347 9.3 27/289 10.3 6/58
Less than 65 years old with ADR 15.7 22/140 16.7 20/120 10.0 2/20
65–74 years old with ADR 0 0/74 0 0/55 0 0/19
75–84 years old with ADR 6.0 5/84 2.9 2/70 21.4 3/14
85 years old and above with ADR 12.2 6/49 11.4 5/44 20.0 1/5
Female patients with ADR 27.3 9/33 29.6 8/27 16.7 1/6
Male patients with ADR 72.7 24/33 70.4 19/27 83.3 5/6
a n denotes number of patients experiencing the event, and N denotes the total number of subjects in the particular category.
Abbreviations: DRPs, drug-related problems; ADRs, adverse drug reactions.Therapeutics and Clinical Risk Management 2005:1(1) 46
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our judgment was based on available biochemistry reports.
Moreover, there might be further cases of renal and hepatic
impairment that were missed during analysis. With proper
monitoring, it is possible to substantially reduce such
incidences.
ADR is another important subset of DRPs. Nearly 10%
of inpatients were found to have an ADR, which is higher
than the ADR incidence of 6.7% found in the meta-analysis
of 39 prospective studies from US hospitals (Lazarou et al
1998). However, it was in line with the report from another
study showing 10%–20% of hospitalized patients
experiencing at least one ADR during their hospital stay
(Brennan et al 1991). Since our study was carried out only
on patients prescribed polypharmacy, the only inference that
could be drawn was that the ADR incidence was probably
comparable to international figures.
In evaluating the drugs frequently implicated in ADRs
(Table 4), NSAIDs and ACE inhibitors were ranked the
highest, closely followed by antiepileptics and serotonin-
selective reuptake inhibitors (SSRIs). The drugs implicated
in the present study are again similar to what has been
reported (Courtman and Stallings 1995; Green et al 2000).
This congruency highlights that there is a rationale to focus
more attention on patients prescribed certain drugs or drug
classes.
In the attempt to identify risk factors, our results
supported published findings that the number of drugs taken
by a patient is an important risk factor for ADRs. Definitely,
the use of polypharmacy in patients is sometimes necessary
to control or manage medical conditions. However, a patient
may often be taking a multitude of medications because
medications were used as substitutes for careful diagnostic
maneuvres or effective nonpharmacologic therapies
(Gurwitz et al 1990). Therefore, before prescribing a
medication, it is important to determine if the patient’s
condition is caused by a current medication. It defeats the
purpose if additional agents are prescribed to deal with the
symptoms of adverse drug effects and this in turn potentiates
the problem of polypharmacy.
The study also attempted to estimate the relative risk of
developing ADRs using the age and gender of patients as
risk factors. So far, we know of only one study that
determined the relative risk of age (as a risk factor) in
developing ADR in patients on major polypharmacy (see
McMillan et al 1986). The establishment and knowledge
of the relative importance of various risk indicators would
lead to better risk management strategy among different
patient subgroups.
From our analysis for patients already receiving
polypharmacy, we found that geriatrics had a similar risk in
experiencing an ADR compared with non-geriatrics.
However, this relative risk was increased to 1.23 if we
included only patients who were on major polypharmacy
(10 drugs or more). Although we did not manage to see any
statistically significant correlation between increasing age
and increased likelihood of developing ADR, this could be
due to our small sample size.
Likewise, where gender comparison is concerned, our
results showed that female patients did not have a higher
risk in developing ADRs when compared with male patients.
This finding is contrary to those reported from Denmark
(Hallas et al 1992) and the Netherlands (Veehof et al 1999)
where the relative risk in developing ADRs for female
patients was 1.57 (95% CI: 1.15, 2.14) and 1.46 (95% CI:
1.09, 1.75), respectively. However, there were some
differences in patient characteristics between the studies.
In the Danish study, a total of 1999 patients of all ages,
regardless of whether they were receiving polypharmacy or
not were recruited (Hallas et al 1992). For the Dutch study,
2185 geriatric patients (65 years and older) prescribed
polypharmacy were recruited, and polypharmacy was
defined as long-term use of 2 or more drugs. In comparison,
our inclusion criteria for polypharmacy, defined as 5 or more
drugs, had restricted the number of eligible patients during
the study period. The much bigger sample sizes in the
previous two studies allowed them to be more sensitive in
detecting the correlation between female gender and the risk
of developing ADRs.
Conclusions
In summary, several observations could be drawn from the
study results.
1. Our results established that the situation of drug therapy
related problems in hospitalized patients receiving
polypharmacy in Singapore is comparable to that
occurring in other developed countries. One important
interpretation of this would be that although DRPs have
been studied and reported for the past twenty years,
lessons and experiences from these studies have not
exactly been translated into effective management of
these problems. Further investigations are required to
see what the underlying problem is in the current
healthcare operating system that is causing this failure.
2. Regarding risk factors, our results showed that among
patients with polypharmacy, age and gender may not be
as important as the number of drugs prescribed asTherapeutics and Clinical Risk Management 2005:1(1) 47
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predictors of experiencing a DRP. In our case, neither
older nor female patients showed a higher risk of
developing DRPs, but this may be confounded by our
inclusion criteria. A similar trend was observed in the
developing of ADRs.
3. We also showed that the drugs causing DRPs in this study
are similar to those in overseas studies. Through
identifying drugs that are most likely to cause DRPs,
healthcare professionals could spend more time
monitoring patients prescribed these drugs.
Based on these findings, we would advocate applying the
20/80 principle in business management into clinical risk
management here. By identifying and properly managing
the small percentage of high-risk patients (such as those
with risk factors for developing DRPs and those prescribed
drugs commonly associated with DRPs), we would be able
to minimize or prevent most of these DRPs. We believe that
with such an approach, the rampaging problem of DRPs
can be at least dampened.
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